Journal
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
Volume 4, Issue 9, Pages 632-639Publisher
WILEY
DOI: 10.1002/acn3.438
Keywords
-
Categories
Funding
- Michael J. Fox Foundation for Parkinson Research
- Interdisziplinares Zentrum fur Klinische Forschung (IZKF) of the University Hospital Wurzburg
- Fondazione Grigioni per il Morbo di Parkinson
Ask authors/readers for more resources
Objective: To investigate the association between levodopa-induced dyskinesias and striatal cholinergic activity in patients with Parkinson's disease. Methods: This study included 13 Parkinson's disease patients with peak-of-dose levodopa- induced dyskinesias, 12 nondyskinetic patients, and 12 healthy controls. Participants underwent 5-[(123) I] iodo-3-[2(S)-2-azetidinylmethoxy] pyridine single- photon emission computed tomography, a marker of nicotinic acetylcholine receptors, [(123) I] N-omega-fluoropropyl-2 beta-carbomethoxy-3 beta-(4-iodophenyl) nortropane single-photon emission computed tomography, to measure dopamine reuptake transporter density and 2-[(18) F] fluoro-2-deoxyglucose positron emission tomography to assess regional cerebral metabolic activity. Striatal binding potentials, uptake values at basal ganglia structures, and correlations with clinical variables were analyzed. Results: Density of nicotinic acetylcholine receptors in the caudate nucleus of dyskinetic subjects was similar to that of healthy controls and significantly higher to that of nondyskinetic patients, in particular, contralaterally to the clinically most affected side. Interpretation: Our findings support the hypothesis that the expression of dyskinesia may be related to cholinergic neuronal excitability in a dopaminergic-depleted striatum. Cholinergic signaling would play a role in maintaining striatal dopaminergic responsiveness, possibly defining disease phenotype and progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available